{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004806","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.867464+00:00","generated_at":"2026-06-06T09:56:58.048646+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biotricity receives Nasdaq delisting determination for failure to meet MVLS requirement; intends to appeal","bullets":["Received delisting letter on Jan 30, 2024, for not regaining compliance with $35M MVLS requirement by Jan 29, 2024.","Trading suspension on Nasdaq Capital Market set for Feb 8, 2024, unless the company appeals.","Company plans to request a hearing before the Nasdaq Hearings Panel to appeal and present a compliance plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004806","json":"https://secwatch.observer/filing/0001493152-24-004806.json","markdown":"https://secwatch.observer/filing/0001493152-24-004806.md","text":"https://secwatch.observer/filing/0001493152-24-004806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224004806/0001493152-24-004806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224004806/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:56:58.048646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c00eb10cd5b218fa371c9e2e8920e47194af52c","claim":"BIOTRICITY INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"January 30, 2024, the Company received a delisting determination letter (the “Letter”) from the Staff advising the Company that the Staff had determined that the Company did not regain compliance with the MVLS Requirement by the Compliance Date because the Company’s MVLS did not close at or above $35 million for a minimum of 10 consecutive business days prior to the Compliance Date. As a result, unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock on the Nasdaq Capital Market will be suspended at the opening of business on February 8, 2024","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224004806/0001493152-24-004806-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}